176 related articles for article (PubMed ID: 35758246)
1. WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling.
Cai J; Su L; Luo W
Bioengineered; 2022 Jun; 13(6):14450-14459. PubMed ID: 35758246
[TBL] [Abstract][Full Text] [Related]
2. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
3. Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways.
Kwak AW; Park JW; Lee SO; Lee JY; Seo JH; Yoon G; Lee MH; Choi JS; Shim JH
Phytomedicine; 2022 Oct; 105():154383. PubMed ID: 35987016
[TBL] [Abstract][Full Text] [Related]
4. Echinatin induces reactive oxygen species-mediated apoptosis via JNK/p38 MAPK signaling pathway in colorectal cancer cells.
Kwak AW; Lee JY; Lee SO; Seo JH; Park JW; Choi YH; Cho SS; Yoon G; Lee MH; Shim JH
Phytother Res; 2023 Feb; 37(2):563-577. PubMed ID: 36184899
[TBL] [Abstract][Full Text] [Related]
5. WDR62 mediates TNFα-dependent JNK activation via TRAF2-MLK3 axis.
Prinz E; Aviram S; Aronheim A
Mol Biol Cell; 2018 Oct; 29(20):2470-2480. PubMed ID: 30091641
[TBL] [Abstract][Full Text] [Related]
6. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
Huang C; Zhou T; Ma L; Zhao S
Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
[TBL] [Abstract][Full Text] [Related]
7. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
8. HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
Liu W; Zhang Z; Zhang Y; Chen X; Guo S; Lei Y; Xu Y; Ji C; Bi Z; Wang K
Cancer Biol Ther; 2015; 16(4):511-7. PubMed ID: 25778491
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
10. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
12. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
13. Luteolin impacts deoxyribonucleic acid repair by modulating the mitogen-activated protein kinase pathway in colorectal cancer.
Song Y; Yu J; Li L; Wang L; Dong L; Xi G; Lu YJ; Li Z
Bioengineered; 2022 Apr; 13(4):10998-11011. PubMed ID: 35473479
[TBL] [Abstract][Full Text] [Related]
14. The c-MYC-WDR43 signalling axis promotes chemoresistance and tumour growth in colorectal cancer by inhibiting p53 activity.
Di Y; Jing X; Hu K; Wen X; Ye L; Zhang X; Qin J; Ye J; Lin R; Wang Z; He W
Drug Resist Updat; 2023 Jan; 66():100909. PubMed ID: 36525936
[TBL] [Abstract][Full Text] [Related]
15. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
[TBL] [Abstract][Full Text] [Related]
16. MEKK3 coordinates with FBW7 to regulate WDR62 stability and neurogenesis.
Xu D; Yao M; Wang Y; Yuan L; Hoeck JD; Yu J; Liu L; Yeap YYC; Zhang W; Zhang F; Feng Y; Ma T; Wang Y; Ng DCH; Niu X; Su B; Behrens A; Xu Z
PLoS Biol; 2018 Dec; 16(12):e2006613. PubMed ID: 30566428
[TBL] [Abstract][Full Text] [Related]
17. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
18. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of STRA6 predicts poor prognosis and contributes to oxaliplatin resistance in colorectal cancer.
Yang F; Xu P; Yao S; Li M; Bian Z; Huang Z
Pathol Res Pract; 2023 Mar; 243():154352. PubMed ID: 36758416
[TBL] [Abstract][Full Text] [Related]
20. SUMO2/3 promotes the progression and oxaliplatin resistance of colorectal cancer through facilitating the SUMOylation at Ku80-K307.
Feng D; He J; Yuan M; Chen Q; Zeng X; Zhou Q; Wu J; Han B
Biofactors; 2023; 49(6):1158-1173. PubMed ID: 37338025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
